Professor David Price
Chair of Primary Care Respiratory Med
- About
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 47 of 86 Results 461 to 470 of 858
First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis
npj Primary Care Respiratory Medicine, vol. 26, 16061Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/npjpcrm.2016.61
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/7666/1/npjpcrm201661.pdf
Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up
Multidisciplinary respiratory medicine, vol. 11, 39Contributions to Journals: LettersA practical tool for primary care antimicrobial stewardship in children
The Lancet. Respiratory medicine, vol. 4, no. 11, pp. 850-852Contributions to Journals: Comments and DebatesIncidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device
Respiratory Medicine, vol. 120, pp. 54-63Contributions to Journals: ArticlesFourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations
Trials, vol. 17, 499Contributions to Journals: ArticlesInappropriate asthma therapy-a tale of two countries: a parallel population-based cohort study
npj Primary Care Respiratory Medicine, vol. 26, 16076Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/npjpcrm.2016.76
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/7606/1/npjpcrm201676.pdf
COPD case finding: effective, but also cost-effective?
The Lancet. Respiratory medicine, vol. 4, no. 10, pp. e49Contributions to Journals: Letters- [ONLINE] DOI: https://doi.org/10.1016/S2213-2600(16)30266-1
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal
Applied Health Economics and Health Policy, vol. 14, no. 5, pp. 579-594Contributions to Journals: ArticlesEligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
Respiratory Research, vol. 17, pp. 1-13Contributions to Journals: ArticlesMetabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study
PloS ONE, vol. 11, no. 9, pp. 1-17Contributions to Journals: Articles